Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hepatic encephalopathy.

S H Gammal1, E A Jones

  • 1Liver Diseases Section, National Institutes of Health, Bethesda, Maryland.

The Medical Clinics of North America
|July 1, 1989
PubMed
Summary
This summary is machine-generated.

Hepatic encephalopathy (HE) symptoms improved with flumazenil, a benzodiazepine (BZ) receptor antagonist. This suggests endogenous BZ receptor ligands may worsen HE by enhancing GABA neurotransmission.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Increases in the enzyme activity of mouse mammary explants induced by prolactin.

The Journal of endocrinology·2025
Same author

The role of receptor MAS in microglia-driven retinal vascular development.

Angiogenesis·2019
Same author

Genotype-phenotype correlation in a large English cohort of patients with autosomal recessive ichthyosis.

The British journal of dermatology·2019
Same author

Mesoderm induction in the future tail region of Xenopus.

Roux's archives of developmental biology : the official organ of the EDBO·2017
Same author

Mesenchymal stem cells, autoimmunity and rheumatoid arthritis.

QJM : monthly journal of the Association of Physicians·2014
Same author

To admit or not to admit on the morning of surgery patients' perspectives on day of surgery admission.

Journal of perioperative practice·2013

Area of Science:

  • Neuroscience
  • Hepatology
  • Pharmacology

Background:

  • Hepatic encephalopathy (HE) is a reversible neurological syndrome associated with liver failure.
  • Existing treatments show limited efficacy, necessitating novel therapeutic targets.
  • Animal models and uncontrolled human studies suggest a role for the GABAergic system in HE pathogenesis.

Purpose of the Study:

  • To investigate the potential role of endogenous benzodiazepine (BZ) receptor ligands in the pathophysiology of hepatic encephalopathy (HE).
  • To explore the therapeutic potential of flumazenil, a BZ receptor antagonist, in ameliorating HE symptoms.

Main Methods:

  • Review of recent studies reporting behavioral and electrophysiologic improvements in HE animal models and patients.
  • Analysis of uncontrolled studies involving intravenous administration of flumazenil in patients with fulminant hepatic failure (FHF) or cirrhosis.

Related Experiment Videos

Main Results:

  • Flumazenil administration led to amelioration of HE in animal models of FHF.
  • A majority of patients with FHF or cirrhosis showed improvements following flumazenil treatment in uncontrolled studies.
  • These findings suggest a potential contribution of endogenous BZ receptor ligands to HE.

Conclusions:

  • Endogenous BZ receptor ligands may contribute to HE manifestations by potentiating GABA-mediated neurotransmission.
  • Flumazenil shows promise as a therapeutic agent for HE, warranting further controlled investigation.
  • The GABAergic system represents a potential therapeutic target for managing hepatic encephalopathy.